Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28517707 | 0.83 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4ALDH1A1CHRNA3 | |
| SCHEMBL19546492 | 0.82 | ALDH1A1 (0.41) | CHRNB2CHRNA4CHRNB4ALDH1A1CHRNA3 | |
| SCHEMBL14319857 | 0.80 | GABRP (0.43) | — | |
| SCHEMBL20099695 | 0.78 | ALOX15 (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL26426337 | 0.78 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4ALDH1A1 | |
| SCHEMBL26373651 | 0.76 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNB4ALDH1A1CHRNA3 | |
| SCHEMBL20099675 | 0.75 | CHRNB2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL16923584 | 0.75 | TSHR (0.46) | CHRNB2CHRNA4CHRNB4ALDH1A1CHRNA3 | |
| SCHEMBL23974055 | 0.75 | CHRNB2 (0.33) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL19230440 | 0.75 | TDP1 (0.44) | CHRNB2CHRNA4CHRNB4ALDH1A1CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210851-A1 | SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME | APTINYX INC (US) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210851-A1 | SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME | ACE, ACE2, PREP | CHRNB2 4866/4885CHRNA4 4835/4885CHRNB4 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.